688428 Stock Overview
A biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
InnoCare Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$13.85 |
| 52 Week High | HK$15.15 |
| 52 Week Low | HK$7.28 |
| Beta | 1.02 |
| 1 Month Change | -3.21% |
| 3 Month Change | 18.78% |
| 1 Year Change | 25.79% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 48.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688428 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -4.4% | 1.8% | 2.8% |
| 1Y | 25.8% | -16.5% | 11.4% |
Return vs Industry: 688428 exceeded the CN Biotechs industry which returned -16.5% over the past year.
Return vs Market: 688428 exceeded the CN Market which returned 11.4% over the past year.
Price Volatility
| 688428 volatility | |
|---|---|
| 688428 Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 688428 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688428's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 1,109 | Jasmine Cui | www.innocarepharma.com |
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma.
InnoCare Pharma Limited Fundamentals Summary
| 688428 fundamental statistics | |
|---|---|
| Market cap | CN¥12.68b |
| Earnings (TTM) | -CN¥375.51m |
| Revenue (TTM) | CN¥898.92m |
11.8x
P/S Ratio-28.2x
P/E RatioIs 688428 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688428 income statement (TTM) | |
|---|---|
| Revenue | CN¥898.92m |
| Cost of Revenue | CN¥125.58m |
| Gross Profit | CN¥773.34m |
| Other Expenses | CN¥1.15b |
| Earnings | -CN¥375.51m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 86.03% |
| Net Profit Margin | -41.77% |
| Debt/Equity Ratio | 20.9% |
How did 688428 perform over the long term?
See historical performance and comparison